Mesenchymal stromal cell delivery as a potential therapeutic strategy against COVID-19: Promising evidence from in vitro results

Figure 3 Quantification of immunosuppressive agents after 12 h from the initial activation with coronavirus disease 2019 patient serum. A-D: Quantification of cytokines including IL-1Ra, IL-6, IL-10, and IL-13 in unstimulated and stimulated Wharton’s Jelly (WJ) and bone marrow-mesenchymal stromal cells (BM-MSCs); E-H: Quantification of growth factors including TGF-b1, FGF, VEGFA, and PDGF in unstimulated and stimulated WJ and BM-MSCs; I: Quantification of indoleamine-2,3-dioxygenase in unstimulated and stimulated WJ and BM-MSCs. BM: Bone marrow; MSCs: Mesenchymal stromal cells; WJ: Wharton’s Jelly.